Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene

F. Doffe, V. Carbonnier, M. Tissier, B. Leroy, I. Martins, JSM. Mattsson, P. Micke, S. Pavlova, S. Pospisilova, J. Smardova, AC. Joerger, KG. Wiman, G. Kroemer, T. Soussi

. 2021 ; 28 (5) : 1477-1492. [pub] 20201130

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22012447

Grant support
- Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)
Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)

E-resources Online Full text

NLK Free Medical Journals from 2011
PubMed Central from 2011 to 1 year ago
Europe PubMed Central from 2011 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 33257846
DOI 10.1038/s41418-020-00672-0
Knihovny.cz E-resources

Infrequent and rare genetic variants in the human population vastly outnumber common ones. Although they may contribute significantly to the genetic basis of a disease, these seldom-encountered variants may also be miss-identified as pathogenic if no correct references are available. Somatic and germline TP53 variants are associated with multiple neoplastic diseases, and thus have come to serve as a paradigm for genetic analyses in this setting. We searched 14 independent, globally distributed datasets and recovered TP53 SNPs from 202,767 cancer-free individuals. In our analyses, 19 new missense TP53 SNPs, including five novel variants specific to the Asian population, were recurrently identified in multiple datasets. Using a combination of in silico, functional, structural, and genetic approaches, we showed that none of these variants displayed loss of function compared to the normal TP53 gene. In addition, classification using ACMG criteria suggested that they are all benign. Considered together, our data reveal that the TP53 coding region shows far more polymorphism than previously thought and present high ethnic diversity. They furthermore underline the importance of correctly assessing novel variants in all variant-calling pipelines associated with genetic diagnoses for cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012447
003      
CZ-PrNML
005      
20220506130238.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41418-020-00672-0 $2 doi
035    __
$a (PubMed)33257846
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Doffe, Flora $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France $u Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden
245    10
$a Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene / $c F. Doffe, V. Carbonnier, M. Tissier, B. Leroy, I. Martins, JSM. Mattsson, P. Micke, S. Pavlova, S. Pospisilova, J. Smardova, AC. Joerger, KG. Wiman, G. Kroemer, T. Soussi
520    9_
$a Infrequent and rare genetic variants in the human population vastly outnumber common ones. Although they may contribute significantly to the genetic basis of a disease, these seldom-encountered variants may also be miss-identified as pathogenic if no correct references are available. Somatic and germline TP53 variants are associated with multiple neoplastic diseases, and thus have come to serve as a paradigm for genetic analyses in this setting. We searched 14 independent, globally distributed datasets and recovered TP53 SNPs from 202,767 cancer-free individuals. In our analyses, 19 new missense TP53 SNPs, including five novel variants specific to the Asian population, were recurrently identified in multiple datasets. Using a combination of in silico, functional, structural, and genetic approaches, we showed that none of these variants displayed loss of function compared to the normal TP53 gene. In addition, classification using ACMG criteria suggested that they are all benign. Considered together, our data reveal that the TP53 coding region shows far more polymorphism than previously thought and present high ethnic diversity. They furthermore underline the importance of correctly assessing novel variants in all variant-calling pipelines associated with genetic diagnoses for cancer.
650    _2
$a geny p53 $x genetika $7 D016158
650    _2
$a lidé $7 D006801
650    _2
$a missense mutace $x genetika $7 D020125
650    _2
$a nádory $x genetika $7 D009369
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Carbonnier, Vincent $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
700    1_
$a Tissier, Manon $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
700    1_
$a Leroy, Bernard $u Department of Life Science, Sorbonne Université, Paris, France
700    1_
$a Martins, Isabelle $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France $u Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
700    1_
$a Mattsson, Johanna S M $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
700    1_
$a Micke, Patrick $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
700    1_
$a Pavlova, Sarka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Smardova, Jana $u Faculty of Science, Department of Experimental Biology, Masaryk University, Brno, Czech Republic
700    1_
$a Joerger, Andreas C $u Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe University, Max-von-Laue-Str. 9, 60438, Frankfurt am Main, Germany $u Buchmann Institute for Molecular Life Sciences and Structural Genomics Consortium (SGC), Max-von-Laue-Str. 15, 60438, Frankfurt am Main, Germany
700    1_
$a Wiman, Klas G $u Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/000000027113524X
700    1_
$a Kroemer, Guido $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France $u Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France $u Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France $u Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Soussi, Thierry $u Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France. thierry.soussi@sorbonne-universite.fr $u Department of Oncology-Pathology, Bioclinicum, Karolinska Institutet, Stockholm, Sweden. thierry.soussi@sorbonne-universite.fr $u Department of Life Science, Sorbonne Université, Paris, France. thierry.soussi@sorbonne-universite.fr $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. thierry.soussi@sorbonne-universite.fr $u Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France. thierry.soussi@sorbonne-universite.fr $1 https://orcid.org/0000000181843293
773    0_
$w MED00005364 $t Cell death and differentiation $x 1476-5403 $g Roč. 28, č. 5 (2021), s. 1477-1492
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33257846 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130231 $b ABA008
999    __
$a ok $b bmc $g 1789865 $s 1163648
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 28 $c 5 $d 1477-1492 $e 20201130 $i 1476-5403 $m Cell death and differentiation $n Cell Death Differ $x MED00005364
GRA    __
$a - $p Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)
GRA    __
$p Radiumhemmets Forskningsfonder (Cancer Research Foundations of Radiumhemmet)
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options